Antonio Avallone is a medical oncologist with a long and excellent experience in clinical trials and translational studies. He was a fellow and then staff member of the gastrointestinal medical oncology unit of Institute Pascale and was involved in designing and conducting several clinical trials. In the last years, he has focused his research on antiangiogenesis and in developing original combination approaches between chemotherapeutics and targeted drugs. He is a pioneer in designing adaptive treatment with anti-EGFR in metastatic colorectal cancer. He founded and coordinated, since 2004, in Institute Pascale, a high-skilled multidisciplinary group for gastrointestinal cancer diagnosis and treatment. Moreover, from 2014 to 2019 he directed the Day Hospital Chemotherapy Unit for the treatment of neoplastic disease and from 2016 he has been the Director of Experimental Clinical Abdominal Oncology Unit in Institute Pascale. He is the coauthor of more than130 articles in peer-reviewed scientific journals and he is the principal investigator of more than 30 clinical studies in gastrointestinal diseases. He is a member of the Editorial Board of the scientific journal Cancers and Frontiers in Oncology.